Results 21 to 30 of about 2,751,693 (208)
A Study on BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia from Western India
Background: BCR-ABL kinase domain(KD) mutations accounts for 60-80% of Imatinib resistance in chronic myeloid leukemia (CML) – chronic phase (CP). Patients with CML who are receiving imatinib treatment, a mutation analysis is required to find out the ...
Pankaj Gadhia +4 more
doaj +1 more source
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. [PDF]
Lyczek A +11 more
europepmc +2 more sources
The Potential circRNAs in Imatinib Resistance of GIST [PDF]
Abstract Background: Circular RNAs are a recently (re-)discovered abundant RNA species, belongs to part of the competing endogenous RNA network(ceRNA), Which was proved to play a critical role in the development, diagnosis and progress of diseases. Methods: We analyzed the expression of circular RNAs in paired normal gastric tissues(N), primary
Jingyi Yan +4 more
openaire +2 more sources
Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors
Priyanka Singh +3 more
doaj +1 more source
Chronic myeloid leukemia (CML) patients with complex chromosomal translocations as well as non-compliant CML patients often demonstrate short-lived responses and poor outcomes on the current therapeutic regimes using Imatinib and its variants.
Anusha +7 more
doaj +1 more source
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. [PDF]
BACKGROUND: BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Recent studies indicate the presence of pre-existing BCR-ABL mutations in a higher percentage of CML patients ...
Zafar Iqbal +19 more
doaj +1 more source
Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular ...
Raquel Alves +4 more
doaj +1 more source
CAQ Corner: Basic concepts of transplant immunology
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Background The introduction of imatinib revolutionized the treatment of chronic myeloid leukaemia (CML), substantially extending patient survival. However, imatinib resistance is currently a clinical problem for CML.
Huayao Li +8 more
doaj +1 more source
Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. [PDF]
Dermatofibrosarcoma protuberans (DFSP) is a very rare soft tissue sarcoma. DFSP often reveals a specific chromosome translocation, t(17;22)(q22;q13), which results in the fusion of collagen 1 alpha 1 (COL1A1) gene and platelet-derived growth factor-B ...
Jung Yong Hong +7 more
doaj +1 more source

